# Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

> **NCT03079427** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 101 (actual)

## Conditions studied

- Cholangiocarcinoma
- Biliary Tract Cancer
- Adjuvant Chemotherapy
- Capecitabine
- Gemcitabine
- Cisplatin

## Interventions

- **DRUG:** Gemcitabine plus cisplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03079427
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-15
- **Primary completion:** 2021-12-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2022-12-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03079427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03079427, "Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03079427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*